American Society of Transplant Surgeons

The American Society of Transplant Surgeons is identified in the evidence as a professional body involved in transplant policy and consensus formation. Its clearest documented role is as a co-sponsor of a consensus conference on simultaneous liver-kidney transplantation, where portal hypertension criteria were proposed to help determine whether a well-compensated cirrhotic patient should receive a kidney alone or undergo simultaneous liver-kidney transplantation. This places the Society within the institutional framework translating clinical evidence into organ-allocation and transplant-selection recommendations for patients with advanced liver disease, including those with HCV infection.

Role in Transplant Consensus

The consensus conference was co-sponsored by the American Society of Transplantation, the American Society of Transplant Surgeons, the American Society of Nephrology, and the United Network for Organ Sharing. Its practical problem was how to assess HCV-infected kidney-transplant candidates with cirrhosis who might be considered too healthy for liver transplantation yet might face unacceptable risks from kidney transplantation alone. Rather than relying solely on the label of cirrhosis, the consensus approach proposed portal hypertension as a key discriminator.

The specific recommendation was that patients with a wedge hepatic vein pressure below 10 mm Hg could be listed for kidney transplantation alone, although the recommendation still required validation in practice. Additional criteria used by the authors' programs included the absence of varices on endoscopy and a platelet count above 120 × 10³/µl. Patients with established or decompensated cirrhosis were generally considered for referral to a liver-transplant team for possible simultaneous liver-kidney transplantation. The Society's documented contribution therefore belongs to a wider multidisciplinary effort rather than to an isolated surgical rule.

Connection to HCV and Kidney Transplantation

The Society's consensus role sits within a larger clinical pathway in which HCV infection must be detected, staged, and monitored before kidney transplantation. All candidates are described as requiring screening for anti-HCV antibodies and, where appropriate, active viremia by nucleic acid testing. Patients with active HCV infection should undergo liver assessment, with liver biopsy remaining the reference method for determining the extent of injury because noninvasive tests had not established comparable accuracy.

This staging matters because the risks of kidney transplantation in cirrhotic patients include greater perioperative morbidity and mortality, susceptibility to infectious and metabolic complications, and poorer long-term survival. A single-center series reported only 26% survival at 10 years among the few patients with pretransplant cirrhosis. The consensus framework associated with the American Society of Transplant Surgeons thus addresses a high-stakes boundary: preserving access to kidney transplantation for patients with compensated disease while directing those with more advanced portal-hypertensive or hepatic disease toward combined transplantation.

Institutional Context and Organ Scarcity

The Society's policy role also appears against the background of severe organ scarcity. Worldwide transplantation benefits about 100,000 patients annually, yet the supply of organs remains far below demand. At the end of 2009, approximately 63,000 patients were on waiting lists in the European Union while about 28,000 transplant procedures were performed that year; in the United States, nearly 111,000 patients were registered on the waiting list in May 2011, with roughly 28,000 procedures performed annually. Such shortages force transplant systems to weigh graft risks against the harms of prolonged dialysis and waiting-list mortality.

That same scarcity informs debate over kidneys from HCV-positive donors. HCV is transmissible through organ transplantation, and many centers have historically refused kidneys from HCV-positive donors, with some jurisdictions imposing technical or legal restrictions. Yet HCV-positive kidneys may become surplus organs as treatment and prevention reduce the number of HCV-infected recipients available to receive them. Donated HCV-positive kidneys were reported to be 2.60 times more likely to be discarded than HCV-negative kidneys. The Society is not assigned a direct operational role in this donor-organ policy in the available evidence, but its inclusion among major transplant organizations illustrates the professional network in which such allocation questions are debated.

Relationship to Clinical Governance

The evidence presents the American Society of Transplant Surgeons as one node in a governance structure that joins surgical judgment, nephrology, hepatology, organ allocation, and professional consensus. The resulting recommendations do not eliminate uncertainty: portal-pressure thresholds had not yet been validated in practice, long-term outcomes for HCV-infected kidney recipients with biopsy-proven cirrhosis remained incompletely defined, and the best timing of antiviral treatment before transplantation was unsettled.

The Society's significance therefore lies less in a single intervention than in the organization of difficult choices. Patients with active viremia may be placed on hold and referred for hepatologic assessment; those who achieve a sustained virological response require continued testing to confirm its durability; and those who remain viremic on the waiting list require regular reassessment for progression of liver disease. In this setting, transplant surgery is inseparable from classification, surveillance, organ scarcity, and the selection of an appropriate transplant pathway.